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Abstract 
Aims To retrospectively assess the efficacy of a pragmatic education programme called 
Walking Away from Diabetes (WAD), a single-session intervention aimed at patients who are 
at risk of developing type 2 diabetes mellitus (T2DM). 
Methods Baseline and follow-up data for 6116 patients, identified as ‘at risk of diabetes’ in 
the period April 2012 to March 2016, were assessed for T2DM status in January 2018. Any 
differences in outcome between WAD attenders and non-attenders was explored using 
Kaplan-Meier, Log rank testing and Cox regression analyses.  
Results During the follow-up period, 426 out of 3470 (12.3%) WAD attenders and 349/2646 
(13.2%) non-attenders were diagnosed with T2DM (p-value 0.068, Log rank test). Cox 
regression shows that HbA1C (hazard ratio [HR] 1.23, p-value <0.001) and HDL levels (HR 
0.67, p-value <0.001), rather than WAD attendance (HR 0.89, p-value 0.11), were the main 
two factors associated with progress from ‘at risk’ to T2DM.   
Conclusions Although the wider health impact of the WAD programme was not considered 
here, session attendance does not appear to reduce the risk of developing T2DM. However, 
other factors influence the risk of developing T2DM. It is essential for educational 
programmes, designed to have a preventative effect for people at risk of diabetes, to be 
assessed for short- and long-term efficacy. 
Key Words: diabetes, education, exercise, lifestyle, patient education, diabetes risk. 
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Introduction 
Lifestyle interventions can enable a reduction in risk of developing T2DM.[1,2] This has been 
shown in various randomised controlled trials in a variety of populations.[1,3,4,5] The aim of 
the cited studies was to promote more intense physical activity in conjunction with an 
improvement in healthy diet adherence and weight management for overweight and obese 
patients. ‘Walking Away from Diabetes’ (WAD) is a theory driven, structured education 
programme for people identified at increased risk of T2DM. WAD has been developed 
within the NHS and is based on a previously published study.[6,7,8]  
To date there is only clinical outcome data available on the WAD programme from a 
controlled clinical trial and one-year follow-up.[6] In that study, WAD did have a statistically 
significant positive effect on biomedical and lifestyle outcomes. Therefore, investigating the 
long-term outcomes related to WAD is indicated, to appraise whether WAD intervention 
impacts on the risk of at risk people progressing to diabetes.  
Material & Methods 
Study design 
This concerns a retrospective cohort study, and is classed as a service evaluation in 
accordance with UK Health Research Authority guidelines. Therefore, individual informed 
consent was not obtained from patients to use their data. Caldicott approval was obtained 
from the NHS Trust that holds the data to analyse and publish it.  
WAD programme details 
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The WAD programme is described in more detail elsewhere.[6,8] In summary, it provides 
three hours of structured education for up to 10 people (and a partner/friend) led by two 
trained educators. The programme is aimed at promoting walking and to further enhance 
the physical activity through walking message, patients are issued with a pedometer to self-
monitor the steps they take daily. Other information provided to attendees involve the 
causes, complications and timelines for glucose intolerance and diabetes. Patient at risk of 
developing diabetes as determined by Leicester Diabetes Risk Assessment and/or pre-
diabetic Hba1c levels (42 to 47 mmol/mol).[7] This study cohort includes patients referred to 
WAD by GPs between 1 April 2012 and 31 March 2016, and end date for follow-up was 1 
January 2018 . 
Data sources and analysis 
Baseline demographic and clinical measures were taken in the GP surgery when a patient 
was classified as being at risk of diabetes. These included a patient’s residence postcode, 
sex, age, HbA1C, HDL, cholesterol, and blood pressure. Patient ethnicity was not recorded, 
but the study sample is from a county in England where 96.5 % of the population is White 
British.[9] Index of multiple deprivation deciles were calculated from patients’ postcodes[10] , 
with 1 being the highest degree of deprivation, and data on T2DM diagnosis was extracted 
from a national database maintained by the University of Exeter. For continuous and ordinal 
data, the mean and median, respectively, plus the 95% confidence interval (95% CI) was 
calculated. Differences between WAD attender and non-attender cohorts were assessed 
with Chi-squared test (binary and nominal data) and Mann-Whitney U-test (ordinal and 
continuous data). The rate of diagnosis of T2DM over time was considered with a Kaplan-
Meier plot accompanied by Log rank test for WAD as a factor on its own, and Cox regression 
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analysis for all variables. Data was collated using Microsoft Excel and analysed using SPSS 
v20, and a p-value of 0.05 was considered significant. 
Results 
Across the period that the WAD programme ran in this particular NHS Trust, a total of 7916 
patients were identified as being eligible for attendance in primary care, and referred to the 
WAD team in the diabetes department. Of those, 4420 patients attended and 3496 did not 
(56% attendance rate). Complete datasets, baseline demographic, clinical measurements 
data and diabetes outcome data were available for 6116 people who were identified as 
being at risk of developing T2DM. Therefore, all further data analysis was conducted using 
the dataset for these patients. The mean follow-up time was 52.0 months (95% CI 51.4-52.5) 
for attenders and 48.3 months (95% CI 47.7 – 49.0) for non-attenders (p-value <0.001, 
Mann-Whitney U-test). In total, 426 out of 3470 (12.3%) attenders and 349/2646 (13.2%) 
non-attenders were eventually diagnosed with T2DM during the follow-up period. The 
baseline variable measurements were not identical between the WAD attendance and non-
attendance cohorts. Table 1 summarises that they differed in average age, degree of 
deprivation, HDL level, and cholesterol levels. Those who attended WAD were significantly 
older, less deprived, and had a better cardiovascular health profile.  
When diabetes diagnosis in relation to solely WAD attendance is considered, Log rank 
analysis and Kaplan-Meier plotting (Figure 1) of diabetes diagnosis cases shows that there is 
no significant difference in the number of diabetes cases diagnosed during the follow-up 
period (p-value 0.068, Log rank test). Since this kind of analysis does not take into account 
any confounding factors that may influence whether someone develops diabetes, Cox 
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regression analysis was conducted to determine if any variables are associated with 
diabetes, and if this influences any impact that WAD attendance may have on diabetes 
developing during the follow-up period. Table 2 shows that HbA1C and HDL levels are 
associated most significantly with diabetes risk, both in terms of magnitude (hazard ratio 
[HR]) and statistical significance (p-value). A higher HbA1C level is associated with an 
increased risk of T2DM, whereas conversely a higher HDL level is associated with a lower 
risk of developing diabetes. Variables significantly associated with T2DM risk but with a 
negligible hazard ratio are deprivation score, patient age, and cholesterol. On the other 
hand, WAD attendance is not significantly linked to the risk of developing diabetes, though 
there appears to be a trend to lower risk of diabetes if a patient attends a session (not 
significant at p-value of 0.11).   
 
Discussion 
This retrospective evaluative study set out to appraise if real-life application of the WAD 
programme is significantly associated with a reduction in subsequent T2DM diagnosis in 
subsequent years. At first sight this does not seem to be the case. However, there are a few 
caveats to bear mind mind. Although the sample size is large and average follow-up period 
is considerable, this study is hamstrung by being a retrospective evaluation of the 
effectiveness of the WAD programme. Consequently, fasting glucose, low-density lipid 
profiles and some anthropometric measures such as body mass index are not included in 
the analysis. Neither is any data on pre- and post-attendance exercise levels achieved by 
people in this cohort; this is where a prospective epidemiological study would be 
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advantageous. From the available data it is observed that the non-significant reduction seen 
in T2DM in the WAD attenders can probably be attributed to a multitude of factors. There is 
a difference in baseline composition of the WAD attenders and non-attenders, both in terms 
of clinical and non-clinical parameters. Because the patients were able to choose whether to 
attend or not, rather than being allocated to a specific treatment arm, this could not be 
controlled for. Both high HbA1C and low HDL levels are recognised risk factors for T2DM as 
identified in controlled trials and through meta-analysis.[14,15,16] In absolute terms the 
average follow-up period for non-attenders is 3.7 months shorter, which equates to a 7% 
relative difference in follow-up time ‘to the benefit’ of the non-attendance arm. Despite the 
potential confounding role of HDL and relative difference in follow-up time between 
attenders and non-attenders, the long-term impact of attending a WAD session on diabetes 
risk appears modest and inconclusive. This contrasts to a Finnish diabetes prevention 
programme where short-, medium- and long-term outcomes have been positive.[1, 13] The 
main difference between the Finnish and WAD programme is the number of times the 
patient attended an education session: seven sessions with a nutritionist in first year alone 
vs one single session with a session practitioner, respectively. The achieved attendance 
rates are similar for both programmes, with a >50% participation rate recorded. In this 
present study we did not explore the medium- to long-term wider positive impact that the 
WAD programme may have from a patient-perspective, and therefore one has to be mindful 
that it may have other unintended positive effects bar prevention of T2DM. 
National policy means that the WAD programme has been superseded by the Healthier You: 
NHS Diabetes Prevention Programme that is rolled out across England, using various 
programme delivery providers.[18,19] The limited effectiveness observed in this present 
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evaluation for the WAD programme may be due to a number of reasons, but the intensity of 
the intervention may be the key reason. Similar to the Finnish programme on which it is 
based[20], the ‘Healthier You’ programme involves at numerous (at least 13) education and 
exercise sessions of one to two hours each. The potential role of confounding factors – 
demographic, anthropometric and clinical – should be taken into account when evaluating 
the new ‘Healthier You’ programme.  Early indications are that similar trends are observed 
as in the WAD cohort, with older, female patients more likely to attend.[21] 
 
Conclusions 
The single-session WAD education programme may not significantly slow down the rate of 
T2DM manifesting in people at risk of diabetes. More recent published data suggest that 
extended and more intense education programmes may be more effective in preventing 
progression to diabetes. However, evaluations of programmes need to be mindful of 
confounding variables such as patients’ lipid profiles, and potential non-intended health 
benefits that a programme may bring.  
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3-5 very short Key messages. Abbreviations and acronyms list (don't state in full in text). 
 
 
Key messages 
   P a g e  | 12  
            
 
- Evaluative data on the long-term diabetes prevention effect of a single 
educational session for at risk people is lacking. 
- The protective effect of attending the NHS-developed Walking Away from 
Diabetes (WAD) programme appears to be limited, though effectiveness analysis 
should take into account the role of confounding factors. 
- More intense educational programmes have been introduced in the NHS 
recently; however, as for WAD their effectiveness should be measured  with 
other variables (including e.g. high density lipid levels) taken into account. 
 
 
Abbreviations and acronyms list 
- HbA1C, haemoglobin A1C 
- HDL, high density lipids 
- HR, Hazard Ratio 
- NHS, National Health Service 
- T2DM, Type 2 diabetes mellitus 
- WAD, Walking Away from Diabetes 
 
 
 
 
 
 
   P a g e  | 13  
            
 
 
 
 
 
 
 
 
 
 
 
 
 
   P a g e  | 14  
            
 
 
 
 
 
 
 
 
 
 
 
 
Table 1, baseline demographics and clinical measures for patients referred to Walking Away 
from Diabetes programme.  
Variable WAD attenders  
(n = 3470) 
WAD non-attenders 
(n = 2646) 
p-value 
Age, years, mean  
(95% CI) 
66  
(66-67) 
63  
(63-64) 
<0.001~ 
Sex, n, male / female  
(%) 
1527 / 1943  
(44% / 56%) 
1228 / 1418  
(46% / 54%) 
0.061# 
Index of Multiple Deprivation, 
decile , median (95% CI) 
6  
(5.81-5.98) 
6  
(5.44-5.64) 
<0.001~ 
HbA1C, mmol/mol, mean  44.2  44.2  0.16~ 
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(95% CI) (44.1-44.3) (44.1-44.2) 
Blood pressure systolic, mmHg, 
mean  
(95% CI) 
133.9  
(133.4-134.4) 
133.9  
(133.3-134.5) 
0.81~ 
Blood pressure diastolic, mmHg, 
mean  
(95% CI) 
78.1  
(77.7-78.4) 
78.4  
(78.0-78.8) 
0.30~ 
HDL, mmol/L, mean  
(95% CI) 
1.48  
(1.46-1.50) 
1.43  
(1.41-1.45) 
<0.001~ 
Total Cholesterol, mmol/L, mean  
(95% CI) 
4.91  
(4.86-4.95) 
4.99  
(4.84-5.04 
0.007~ 
#Chi-squared test; ~Mann-Whitney U-test; 95% CI, 95% confidence interval 
Table 2, Cox regression analysis for diabetes as outcome and follow-up in months as time 
factor.  
Variable  Hazard Ratio# 95% CI  p-value 
Deprivation index rating (1 = most deprived, to 
10 = least deprived) 
0.97 0.94 – 0.99 0.018* 
Patient sex (0 = male; 1 = female) 1.16 0.99 – 1.35 0.056 
Patient age (years) 0.99 0.98 – 1.00 0.019* 
WAD attendance (0 = non-attendance; 1 = 
attendance) 
0.89 0.77 – 1.03 0.11 
Blood pressure systolic (mmHg) 1.00 0.99 – 1.01 0.78 
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Blood pressure diastolic (mmHg) 1.01 0.99 – 1.01 0.31 
HbA1C (mmol / mol) 1.23 1.21 – 1.24 <0.001* 
HDL (mmol/L) 0.67 0.56 – 0.81 <0.001* 
Cholesterol (mmol/L) 0.91 0.86 – 0.96 0.001* 
*Statistically significant, p-value <0.05. #HR score of > 1 indicates that increased value for 
variable is associated with increased risk of developing diabetes; conversely, HR of < 1 
indicates that increased value of variable is associated with decreased risk of developing 
diabetes.  
 
 
